GSK PLC - London-based pharmaceuticals company - GSK Non-Executive Chair Jonathan Symonds buys 2,500 shares, at a price of GBP21.14, worth GBP52,850, on Thursday in London. Read More
(Alliance News) - Stock prices in London opened lower on Friday, as renewed fears around artifical intelligence investment spread from the US while software and data stocks came under pressure. Read More
(Alliance News) - GSK PLC on Friday said the European Commission has approved Nucala, or mepolizumab, as add-on therapy for adults with chronic obstructive pulmonary disease. Read More
(Alliance News) - UK house prices rise more sharply than expected, GSK wins approval for Nucala to treat chronic obstructive pulmonary disease in the EU, while Victrex backs its annual guidance. Read More
(Alliance News) - Stocks in London slumped on Thursday, tracking US and European counterparts, as investors weighed rate calls in Europe and the UK and as merger talks between Glencore and Rio Tinto collapsed once more. Read More
(Alliance News) - The FTSE 100 surged to a fresh high on Wednesday, spurred by strong trading updates and as insurer Beazley said it has accepted a possible GBP8.0 billion bid. Read More
(Alliance News) - Stock prices in London were higher at midday on Wednesday, despite ongoing jitters over the impact of the latest artificial intelligence developments, as Beazley, DCC and GSK helped the FTSE 100 reach a fresh record. Read More
(Alliance News) - GSK PLC on Wednesday backed guidance after fourth-quarter results beat expectations, driven by growth in its Specialty Medicines and Vaccines divisions and lower-than-expected expenses. Read More
(Alliance News) - Beazley agrees to takeover terms for a GBP8.0 billion takeover by Zurich Insurance, while GSK reports "another strong performance" helped by its Specialty Medicines arms. Read More
(Alliance News) - The FTSE 100 shrugged off a weak start, and further volatility in metals and oil prices, to hit new highs on Monday, amid optimism in the manufacturing sector on either side of the pond. Read More
(Alliance News) - Drugs firm GSK PLC is axing up to around 350 research and development jobs across the US and UK as part of an ongoing overhaul of the division. Read More
(Alliance News) - Stock prices in London closed mostly higher on Thursday, as investors digested the US Federal Reserve's Wednesday decision to stand pat on interest rates. Read More
(Alliance News) - Pharmaceutical firm AstraZeneca PLC on Thursday unveiled plans to invest USD15 billion in China through to 2030, in an announcement that coincides with UK Prime Minister Keir Starmer's visit to Beijing. Read More
(Alliance News) - The UK pub sector awaits a GBP100 million support package from the Treasury aimed at easing cost pressures, the Financial Times reports, while Sage posts 10% quarterly revenue growth and Dr Martens reports a dip in third-quarter revenue. Read More
(Alliance News) - GSK PLC on Monday said the European Commission has approved an expanded indication for its respiratory syncytial virus vaccine Arexvy, allowing use in all adults aged 18 and over. Read More
(Alliance News) - GSK wins EU approval to expand use of its RSV vaccine Arexvy to all adults over 18, while Grainger unveils plans for a 195-home West London development, and Impax Environmental Markets outlines its tender offer plan amid continued pressure from activist investor Saba. Read More